A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
Completed · Phase 1 · Has a placebo group
Conditions studied: HIV Infections
In brief
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGDM1400 and PGT121 and VRC07-523LS mAbs for HIV prevention and therapy.
Key facts
- Study ID
- NCT03205917
- Run by
- International AIDS Vaccine Initiative
- People needed
- 29
- Starts
- 2017-10-23
- Expected to finish
- 2020-04-20
- Last updated by the study team
- 2020-09-14
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.